Gainers

• Liminatus Pharma (NASDAQ:LIMN) stock increased by 24.3% to $1.33 during Wednesday's pre-market session. The company's market cap stands at $28.9 million.
• Oncolytics Biotech (NASDAQ:ONCY) shares rose 16.76% to $1.02. The company's market cap stands at $94.4 million.
• Ensysce Biosciences (NASDAQ:ENSC) stock rose 14.81% to $0.7. The company's market cap stands at $2.1 million.
• PDS Biotechnology (NASDAQ:PDSB) shares rose 10.41% to $0.84. The market value of their outstanding shares is at $41.8 million.
• Valneva (NASDAQ:VALN) stock increased by 10.36% to $10.01. The market value of their outstanding shares is at $786.4 million.
• Lunai Bioworks (NASDAQ:LNAI) stock increased by 10.01% to $0.78. The market value of their outstanding shares is at $16.6 million.

Losers

• Concord Medical Services (NYSE:CCM) shares declined by 10.3% to $3.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $169.3 million.
• Boston Scientific (NYSE:BSX) shares fell 9.27% to $83.13. The market value of their outstanding shares is at $135.8 billion. As per the press release, Q4 earnings came out today.
• CDT Equity (NASDAQ:CDT) stock declined by 9.03% to $1.21. The company's market cap stands at $3.0 million.
• VSee Health (NASDAQ:VSEE) shares declined by 7.43% to $0.32. The company's market cap stands at $11.3 million.
• Cencora (NYSE:COR) stock decreased by 6.84% to $337.01. The market value of their outstanding shares is at $70.3 billion. The company's, Q1 earnings came out today.
• NewGenIvf Group (NASDAQ:NIVF) shares fell 6.26% to $1.2. The company's market cap stands at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.